Tiziana Life Sciences Ltd

Equities

TLSA

BMG889121031

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
0.7901 ^USD	+1.95%		+54.02%	+41.09%

Apr. 23	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT
Apr. 23	Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program	MT

Tiziana Life Sciences Ltd Reports Earnings Results for the Full Year Ended December 31, 2021

May 23, 2022 at 06:06 am EDT

Tiziana Life Sciences Ltd reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 23.42 million compared to USD 26.13 million a year ago. Basic loss per share from continuing operations was USD 0.239 compared to USD 0.2685 a year ago.

Latest news about Tiziana Life Sciences Ltd

Sector Update: Health Care Stocks Rise in Afternoon Trading	Apr. 23	MT
Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program	Apr. 23	MT
Tiziana Life Sciences, Ltd. Announces FDA Allowance for Additional Twenty Patients to Be Enroll in Intranasal Foralumab Multiple Sclerosis Expanded Access Program	Apr. 23	CI
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in Its Expanded Access Program	Apr. 22	CI
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with Pira Highlighted in Neurology	Apr. 19	CI
Tiziana Life Sciences Ltd. Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology	Apr. 18	CI
Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients	Jan. 08	CI
Tiziana Life Sciences Seeks Patent for Combination Therapy for Inflammation Linked to Type 2 Diabetes, Obesity	Jan. 05	MT
Tiziana Life Sciences Ltd Files New Patent Application for Combination Therapy of anti-CD3 with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation	Jan. 05	CI
Tiziana Life Sciences Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	Dec. 30	CI
Tiziana Life Sciences Ltd. Doses First Patient in Phase 2A Trial of Intranasal Foralumab in Multiple Sclerosis	Dec. 19	CI
Transcript : Tiziana Life Sciences Ltd - Shareholder/Analyst Call	Dec. 14
Tiziana Life Sciences Doses Four New Patients in Multiple-Sclerosis Program	Nov. 30	MT
Tiziana Life Sciences Ltd. Announces Successfully Enrolled and Dosed Four New Patients with Non-Active Secondary Progressive Multiple Sclerosis	Nov. 30	CI
Tiziana Life Sciences Says FDA Allows At-Home Use of Multiple Sclerosis Treatment; Shares Rise	23-10-18	MT
Tiziana Life Sciences Ltd. Announces Allowance by Fda for At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis Treatment	23-10-18	CI
Tiziana Life Sciences Ltd. Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab	23-10-16	CI
Tiziana Life Sciences Says Multiple Sclerosis Drug Reduced Key Biomarker Based on PET Scan Results	23-10-13	MT
Tiziana Announces Positive Qualitative Six-Month Pet Scan Results with Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed with Non-Active Secondary Progressive MS (Na-SPMS)	23-10-13	CI
Tiziana Life Sciences Initiates Phase 2a Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis	23-09-26	MT
Tiziana Life Sciences Ltd. Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis	23-09-26	CI
BMW expects higher China sales in 2023, finance chief says	23-09-02	RE
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer, Effective September 1, 2023	23-08-23	CI
Sector Update: Health Care Stocks Declining in Late Afternoon Trading	23-08-15	MT
Sector Update: Health Care Stocks Easing Tuesday Afternoon	23-08-15	MT

Chart Tiziana Life Sciences Ltd

Duration

Period

More charts

Company Profile

Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohnâs and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TIZIANA LIFE SCIENCES LTD	+41.09%	77.74M
IQVIA HOLDINGS INC.	+4.09%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+9.45%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.47B
MEDPACE HOLDINGS, INC.	+29.70%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.33B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.03B

Other Biotechnology & Medical Research